US FDA Grants RMAT Requests At Similar Rate To Breakthrough Designations

 
• By Bridget Silverman
  
Regenerative medicine
RMAT designees are slower to receive full FDA approval than those with breakthrough therapy designations. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards